| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 09/04/2002 | CN1090028C Medicine for treatment of restenosis and arteriosclerosis |
| 09/03/2002 | US6444821 Humidity-controlling the crystals of n-(2-(4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-piperidino)ethyl)-1-formyl-4 -piperidinecarboxamide hydrochloride anhydride |
| 09/03/2002 | US6444817 Anticoagulants |
| 09/03/2002 | US6444677 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/03/2002 | US6444672 Heterocyclic derivatives and their use as antithrombotic agents |
| 09/03/2002 | US6444644 Peptide having specified amino acid sequence; used for inhibition of thromboplastin |
| 09/03/2002 | US6444434 Compounds inhibiting the activation of fx to fxa by tf/fviia. the compounds are anticoagulants. the invention also relates to a method of identifying a drug candidate. |
| 09/03/2002 | US6444418 Plasma-like solution |
| 09/03/2002 | CA2140626C Hydroxamic acid derivatives as metalloproteinase inhibitors |
| 09/03/2002 | CA2079778C Inhibitors of thrombin |
| 08/29/2002 | WO2002066648A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066498A2 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 08/29/2002 | WO2002066475A2 Tricyclic androgen receptor modulator compounds |
| 08/29/2002 | WO2002066450A2 Anthrone derivatives and their use as ink inhibitors |
| 08/29/2002 | WO2002066431A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same |
| 08/29/2002 | WO2002066427A2 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof |
| 08/29/2002 | WO2002066421A1 Rgd-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects |
| 08/29/2002 | WO2002066418A2 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor |
| 08/29/2002 | WO2002066050A1 Casoase 3 inhibitors |
| 08/29/2002 | WO2002066040A2 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 08/29/2002 | WO2002066035A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/29/2002 | WO2002066034A1 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 08/29/2002 | WO2002065987A2 Production of platelet rich plasma and autologous procoagulant |
| 08/29/2002 | WO2002065978A2 Functional agent for decomposing nicotine and method of preparing the same |
| 08/29/2002 | WO2002042273A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002037937A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002028858A3 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 08/29/2002 | WO2002026718A3 Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| 08/29/2002 | WO2002022621A3 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 08/29/2002 | WO2002022620A3 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f2$g(a) antagonists |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002002506A3 Compounds to treat alzheimer's disease |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001094330A3 Methods for producing amino substituted chromanes |
| 08/29/2002 | WO2001017530A9 Iron chelators and uses thereof |
| 08/29/2002 | WO2001012584A3 Pharmaceutical compounds |
| 08/29/2002 | WO2000068188A9 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 08/29/2002 | WO2000037502A9 Vascular endothelial cell growth factor antagonists and uses thereof |
| 08/29/2002 | WO2000033894A9 Collagen hemostatic foam |
| 08/29/2002 | US20020120948 Modulating gene expression by regulation of cell proliferation; regulated transgene expression in lymphocytes by selective increase in the number of lymphocytes upon exposure to an antigen |
| 08/29/2002 | US20020120156 Preparation of warfarin sodium from warfarin sodium-2-propanol clathrate |
| 08/29/2002 | US20020120147 Micronized torsemide |
| 08/29/2002 | US20020120102 Native Arg-Gly-Asp (RGD) motif has been deleted or has been replaced by an amino acid sequence having no integrin- binding activity, or an integrin-binding amino acid sequence other than RGD which contains aspartic acid or glutamic acid |
| 08/29/2002 | US20020120098 Enhanced stimulation of erythropoiesis |
| 08/29/2002 | US20020120007 Benzamide inhibitors of factor Xa |
| 08/29/2002 | US20020119992 Anticoagulants |
| 08/29/2002 | US20020119988 Modulators of TNF-alpha signaling |
| 08/29/2002 | US20020119986 Heteroaryl- phenyl heterobicyclic factor Xa inhibitors |
| 08/29/2002 | US20020119977 Antitumor agents; antiinflammatory agents; analgesics; antipyretic agent |
| 08/29/2002 | US20020119973 Antiinflammatory agents |
| 08/29/2002 | US20020119968 Protease inhibitor |
| 08/29/2002 | US20020119967 Autoimmune diseases; administering phosphodiesterases inhibitor |
| 08/29/2002 | US20020119964 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| 08/29/2002 | US20020119956 Using thalidomine |
| 08/29/2002 | US20020119932 RGD-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects |
| 08/29/2002 | US20020119931 Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity |
| 08/29/2002 | US20020119519 Nucleotide sequences coding preferential polyeptide for use in the treatment of cancer, kidney and respiratory disorders |
| 08/29/2002 | US20020119202 For therapy of cancer and other angiogenic-dependent diseases |
| 08/29/2002 | US20020119191 Pharmaceutical or food composition for treatment or prevention of brain edema |
| 08/29/2002 | US20020119164 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 08/29/2002 | US20020119151 CD154 blockade therapy for therapeutic protein inhibitor syndrome |
| 08/29/2002 | US20020119144 Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents |
| 08/29/2002 | CA2451089A1 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 08/29/2002 | CA2439193A1 Casoase 3 inhibitors |
| 08/29/2002 | CA2438769A1 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 08/29/2002 | CA2438682A1 Antibodies that bind both bcma and taci |
| 08/29/2002 | CA2438312A1 Anthrone derivatives and their use as jnk inhibitors |
| 08/29/2002 | CA2438235A1 Neurotransmission-associated proteins |
| 08/29/2002 | CA2432208A1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same |
| 08/28/2002 | EP1234821A1 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient |
| 08/28/2002 | EP1234027A1 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1234025A1 Human enzymes of the metalloprotease family |
| 08/28/2002 | EP1233986A1 Reduced side-effect hemoglobin compositions |
| 08/28/2002 | EP1233975A1 29 human secreted proteins |
| 08/28/2002 | EP1233959A1 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents |
| 08/28/2002 | EP1233951A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 08/28/2002 | EP1233950A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS |
| 08/28/2002 | EP1233781A1 Assays and therapies for latent viral infection |
| 08/28/2002 | EP1233778A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 08/28/2002 | EP1233777A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 08/28/2002 | EP1233767A1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 08/28/2002 | EP1233756A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 08/28/2002 | EP0877626B1 Anti-cd18 antibodies for use against stroke |
| 08/28/2002 | EP0862454B1 Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8 for treating infections |
| 08/28/2002 | EP0772452B1 Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor viii |
| 08/28/2002 | EP0716607B1 Biochemically balanced peritoneal dialysis solutions |
| 08/28/2002 | EP0671905B1 Stable protein: phospholipid compositions and methods |
| 08/28/2002 | CN1365791A Nano medicine 'Shenrong Baotai' and its preparing process |
| 08/28/2002 | CN1365771A Nano medicine 'Liuyi' and its preparing process |
| 08/28/2002 | CN1365752A Nano sheep gallbladder medicine and its preparing process |
| 08/28/2002 | CN1365693A Nano medicine for treating cervical cancer and its preparing process |
| 08/28/2002 | CN1365679A Nano medicine 'Anyang' and its preparing process |
| 08/28/2002 | CN1365677A Nano medicine 'Compound spatholobus stem' and its preparing process |
| 08/28/2002 | CN1365665A Synergistic composition containing ascobic acid salt and lysine used for diseases related with extracellular substrate degeneration |
| 08/28/2002 | CN1089764C Substituted heterocyclic compounds, preparation method thereof and pharmaceutical compositions containing same |
| 08/27/2002 | US6441168 Stable crystalline salts of 5-methyltetrahydrofolic acid |
| 08/27/2002 | US6441141 Synthetic peptides, antibodies against them and their use |
| 08/27/2002 | US6441137 Tie-2 ligands; tie= ?tyrosine kinase with ig (immunoglobulins) and egf (epidermal growth factor) homology domains?; tumor neovascularization |